Golden Helix and United Devices Collaborate to Grid-Enable Genetic Analysis, Drug Discovery Software
News Mar 23, 2007
United Devices, which provides secure grid computing solutions to seven of the world's ten largest pharmaceutical companies, said the collaboration would be based on its widely adopted Grid MP™ platform.
Grid computing allows researchers to apply the power of a wide range of an organization's dedicated and non-dedicated computing resources to run specific applications, such as HelixTree and PBAT. From single cluster management implementations to enterprise application virtualization, Grid MP deployments are proven to increase productivity and performance.
"We are excited to be the first to bring truly high performance computing to the SNP analysis market," said Josh Forsythe, director of marketing for Golden Helix.
"Our customers have voiced concerns over how a lack of computing power limits their ability to perform groundbreaking research. With our new distributed capabilities, analyses that used to take our customers vast amounts of time to perform can now be completed in just minutes," Forsythe continued.
HelixTree and PBAT are multi-platform applications that incorporate a suite of analysis tools for candidate gene and genome-wide association studies (GWAS). GWAS involve the simultaneous analysis of tens of billions of single nucleotide polymorphisms (SNPs), genetic markers used to discover genes that cause disease and clinical outcomes.
"With most of the world's largest pharmaceutical companies using Golden Helix applications and simultaneously operating grids based on United Devices technology, it makes perfect sense for our two companies to initiate this strategic partnership," said Alex Lynch, director of strategic alliances at United Devices.
"Together we can provide scientists with computing power that will speed their innovation for the benefit of mankind and the success of their respective companies," Lynch added.
As development efforts are completed, other Golden Helix products will be grid-enabled such as the company's popular ChemTree software, a drug discovery tool that facilitates intelligent, target specific compound selection for High Throughput Screening (HTS), Golden Helix said.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.